Ensysce Biosciences is focused on developing best-in class medications for use in pain management and ADHD. Our abuse-resistant opioid drug technology TAAP has broad potential across all known prescription opioid drugs and a variety of other drugs that have the potential for abuse. PF614 is our lead abuse-resistant opioid drug program. We have made it our priority program due to the crisis of oxycodone abuse and the urgent need for a more abuse-resistant form of this important pain therapy. In January 2018, FDA granted Fast Track designation for development of PF614. We have achieved human proof of concept for our prodrug approach with PF329, our hydromorphone prodrug.